The London-listed firm is already among the leading players in the global race to develop a successful vaccine against COVID-19.
World Reuters
Updated: August 25, 2020 1:58 pm IST
AstraZeneca is already among the leading players in the race to develop a vaccine against COVID-19
British drugmaker AstraZeneca has begun testing an antibody-based cocktail for the prevention and treatment of COVID-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.
The London-listed firm, already among the leading players in the global race to develop a successful vaccine, said the study would evaluate if AZD7442, a combination of two monoclonal antibodies (mAbs), was safe and tolerable in up to 48 healthy participants between the ages of 18 and 55 years.
If the UK-based early-stage trial, which has dosed its participants, shows AZD7442 is safe, AstraZeneca said it would proceed to test it as both a preventative treatment for COVID-19 and a medicine for patients who have it, in larger, mid-to-late-stage studies.
AstraZeneca shares were up about 1% at 87 pounds ($114) in early trading.
Development of mAbs to target the virus, an approach already being tested by Regeneron, ELi Lilly, Roche and Molecular Partners, has been endorsed by leading scientists.
Promoted: In Stores
Kitchen Appliances on Up to 50% Off
Shop them now
Latest Smartphones in every range
Explore Now
Apple iPhone 11 (64GB) - Black
₹ 59,900 (12% off)
Buy
Vlogger Central From ₹ 699
Curated Picks
Revamp your home in style
Explore Now
Shop From Top Audio Store
Up to 60% off
mAbs mimic natural antibodies generated in the body to fight off infection and can be synthesised in the laboratory to treat diseases in patients. Current uses include treatment of some types of cancers.
U.S. infectious diseases expert Anthony Fauci has called them "almost a sure bet" against COVID-19, and AstraZeneca in June received $23.7 million in funding from U.S. government agencies to advance development of antibody-based treatments for COVID-19.
So informative, thanks